| 摘要: |
| ［摘要］ 目的 比较不同剂量阿托伐他汀治疗非ST段抬高型急性冠脉综合征患者的临床效果。方法 选取2017-01～2018-12间住院治疗的41例非ST段抬高型急性冠脉综合征患者，采用随机数字表法将其分为治疗组(n=21)和对照组(n=20)。两组患者均予常规治疗，治疗组在常规用药基础上加用20 mg阿托伐他汀；对照组在常规治疗基础上第1天口服80 mg阿托伐他汀，后继续服用阿托伐他汀40 mg/d，疗程均为6个月。比较两组患者治疗前后不同时间总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、三酰甘油（TG）等指标改变情况及心血管事件发生情况。结果 治疗组与对照组在治疗后2周、4周及24周的血清TC、TG、LDL-C水平均低于治疗前，差异均有统计学意义(P<0.05)；在治疗后2周及4周时，对照组TC、LDL-C水平低于治疗组，而TG水平高于治疗组，差异均有统计学意义(P<0.05)。在治疗24周时，治疗组与对照组TC、LDL-C、TG水平及心血管不良事件发生率比较差异无统计学意义(P>0.05)。结论 阿托伐他汀(20 mg/d)与阿托伐他汀(40 mg/d)治疗非ST段抬高型急性冠脉综合征，在降低血脂及减少心血管不良事件的发生上有着相似的作用，值得临床推广应用。 |
| 关键词: 非ST段抬高型急性冠脉综合征 不同剂量 阿托伐他汀 临床效果 |
| DOI：10.3969/j.issn.1674-3806.2019.10.07 |
| 分类号:R 543.3 |
| 基金项目:东莞市社会科技发展项目（编号：2018507150361525） |
|
| Effects of different doses of atorvastatin on patients with non-ST segment elevation acute coronary syndromes |
|
LIU Yong, LIU Yan-li, MO Song-liu, et al.
|
|
Department of Internal Medicine Ward Ⅱ, Qiaotou Hospital of Dongguan City, Guangdong 523538, China
|
| Abstract: |
| ［Abstract］ Objective To compare the clinical effects of different doses of atorvastatin on treatment of non-ST segment elevation acute coronary syndromes(NSTE-ACS). Methods A total of 41 patients with NSTE-ACS who were hospitalized from January 2017 to December 2018 were divided into treatment group(n=21) and control group(n=20) by random number table method. The patients in both groups received routine treatment. The treatment group received atorvastatin 20 mg in addition to the routine treatment. The control group received atorvastatin 80 mg orally on the first day after routine treatment, followed by atorvastatin 40 mg per day. The course of treatment in both groups was 6 months. The changes of total cholesterol(TC), low density lipoprotein cholesterol(LDL-C) and triglyceride(TG) and the occurrence of cardiovascular events were compared between the two groups before and after treatment. Results The levels of serum TC, TG and LDL-C in the two groups 2, 4 and 24 weeks after treatment were significantly lower than those before treatment(P<0.05). The levels of serum TC and LDL-C in the control group were significantly lower than those in the treatment group 2 and 4 weeks after treatment, and the levels of TG were significantly higher than those in the treatment group(P<0.05). There were no significant differences in the levels of serum TC, LDL-C and TG and the incidence of adverse cardiovascular events between the treatment group and the control group 24 weeks after treatment(P>0. 05). Conclusion Moderate intensity atorvastatin(20 mg/d) is similar to high intensity atorvastatin(40 mg/d) on reducing the blood lipid level and the occurrence of adverse cardiovascular events in NSTE-ACS patients. |
| Key words: Non-ST segment elevation acute coronary syndromes(NSTE-ACS) Different doses Atorvastatin Clinical effect |
